Published in BMC Genomics on November 14, 2012
Cell shape and the microenvironment regulate nuclear translocation of NF-κB in breast epithelial and tumor cells. Mol Syst Biol (2015) 1.11
Differences and homologies of chromosomal alterations within and between breast cancer cell lines: a clustering analysis. Mol Cytogenet (2014) 0.99
Long chain fatty Acyl-CoA synthetase 4 is a biomarker for and mediator of hormone resistance in human breast cancer. PLoS One (2013) 0.93
Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness. Neoplasia (2014) 0.90
Genomic Complexity Profiling Reveals That HORMAD1 Overexpression Contributes to Homologous Recombination Deficiency in Triple-Negative Breast Cancers. Cancer Discov (2015) 0.90
Pharmacological levels of Withaferin A (Withania somnifera) trigger clinically relevant anticancer effects specific to triple negative breast cancer cells. PLoS One (2014) 0.87
PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer. Nat Med (2016) 0.85
Characterization of passive permeability at the blood-tumor barrier in five preclinical models of brain metastases of breast cancer. Clin Exp Metastasis (2016) 0.83
Metaplastic breast carcinomas display genomic and transcriptomic heterogeneity [corrected]. . Mod Pathol (2014) 0.81
Development and characterization of two human triple-negative breast cancer cell lines with highly tumorigenic and metastatic capabilities. Cancer Med (2016) 0.81
Modulation of the tumor microenvironment and inhibition of EGF/EGFR pathway: novel anti-tumor mechanisms of Cannabidiol in breast cancer. Mol Oncol (2015) 0.81
Enriched transcription factor signatures in triple negative breast cancer indicates possible targeted therapies with existing drugs. Meta Gene (2015) 0.81
Profiling the tyrosine phosphoproteome of different mouse mammary tumour models reveals distinct, model-specific signalling networks and conserved oncogenic pathways. Breast Cancer Res (2014) 0.79
Cell shape and the microenvironment regulate nuclear translocation of NF-κB in breast epithelial and tumor cells. Mol Syst Biol (2015) 0.79
Expression of base excision repair key factors and miR17 in familial and sporadic breast cancer. Cell Death Dis (2014) 0.78
Genome-wide effects of MELK-inhibitor in triple-negative breast cancer cells indicate context-dependent response with p53 as a key determinant. PLoS One (2017) 0.75
Selective isolation and characterization of primary cells from normal breast and tumors reveal plasticity of adipose derived stem cells. Breast Cancer Res (2016) 0.75
Identification of clinically predictive metagenes that encode components of a network coupling cell shape to transcription by image-omics. Genome Res (2016) 0.75
Breast cancer subtype dictates DNA methylation and ALDH1A3-mediated expression of tumor suppressor RARRES1. Oncotarget (2016) 0.75
Lippia origanoides extract induces cell cycle arrest and apoptosis and suppresses NF-κB signaling in triple-negative breast cancer cells. Int J Oncol (2017) 0.75
Glycoproteins in Claudin-Low Breast Cancer Cell Lines Have a Unique Expression Profile. J Proteome Res (2017) 0.75
Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A (2001) 132.88
Molecular portraits of human breast tumours. Nature (2000) 94.14
Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A (2003) 34.68
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell (2006) 27.36
Java Treeview--extensible visualization of microarray data. Bioinformatics (2004) 24.12
Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol (2009) 22.22
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature (2012) 20.47
Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature (2010) 19.68
lumi: a pipeline for processing Illumina microarray. Bioinformatics (2008) 17.19
Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell (2006) 16.05
Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst (2006) 14.60
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest (2011) 14.22
Molecular definition of breast tumor heterogeneity. Cancer Cell (2007) 12.67
The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics (2006) 12.45
Triple-negative breast cancer. N Engl J Med (2010) 11.39
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res (2010) 10.90
Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med (2009) 10.88
Pvclust: an R package for assessing the uncertainty in hierarchical clustering. Bioinformatics (2006) 10.83
Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol (2007) 10.49
Gene-expression signatures in breast cancer. N Engl J Med (2009) 9.23
High-throughput DNA methylation profiling using universal bead arrays. Genome Res (2006) 8.05
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A (2009) 7.95
Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res (2008) 7.39
Breast cancer molecular profiling with single sample predictors: a retrospective analysis. Lancet Oncol (2010) 6.88
Comparative analysis of algorithms for identifying amplifications and deletions in array CGH data. Bioinformatics (2005) 6.44
Identification of molecular apocrine breast tumours by microarray analysis. Oncogene (2005) 5.27
The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell (2011) 5.06
Triple negative tumours: a critical review. Histopathology (2008) 4.94
Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res Treat (2004) 4.89
Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene (2006) 4.85
BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell (2010) 4.66
Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS One (2009) 4.62
An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol (2007) 4.33
Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest (2006) 3.95
Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis. J Clin Oncol (2008) 3.74
EGFR associated expression profiles vary with breast tumor subtype. BMC Genomics (2007) 3.35
Determination of stromal signatures in breast carcinoma. PLoS Biol (2005) 2.84
The activity status of cofilin is directly related to invasion, intravasation, and metastasis of mammary tumors. J Cell Biol (2006) 2.59
Functional viability profiles of breast cancer. Cancer Discov (2011) 2.44
An intraductal human-in-mouse transplantation model mimics the subtypes of ductal carcinoma in situ. Breast Cancer Res (2009) 2.37
A three-gene model to robustly identify breast cancer molecular subtypes. J Natl Cancer Inst (2012) 2.34
Triple-negative/basal-like breast cancer: review. Pathology (2009) 2.17
Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene (2010) 2.11
Molecular cytogenetic analysis of 11 new breast cancer cell lines. Br J Cancer (1999) 2.05
Genetic alterations and oncogenic pathways associated with breast cancer subtypes. Mol Cancer Res (2009) 2.05
Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. Ann Oncol (2009) 1.97
Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns. Breast Cancer Res (2010) 1.97
An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers. Breast Cancer Res Treat (2009) 1.93
Tumor suppressor p16INK4A regulates polycomb-mediated DNA hypermethylation in human mammary epithelial cells. J Biol Chem (2006) 1.93
Transcriptionally repressed genes become aberrantly methylated and distinguish tumors of different lineages in breast cancer. Proc Natl Acad Sci U S A (2011) 1.82
Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas. J Pathol (2010) 1.79
A refined molecular taxonomy of breast cancer. Oncogene (2011) 1.78
Tiling path genomic profiling of grade 3 invasive ductal breast cancers. Clin Cancer Res (2009) 1.68
Cyclin D1 protein overexpression and CCND1 amplification in breast carcinomas: an immunohistochemical and chromogenic in situ hybridisation analysis. Mod Pathol (2006) 1.62
Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis. Clin Cancer Res (2007) 1.61
Breast cancer stem cells: tools and models to rely on. BMC Cancer (2009) 1.38
DNA copy number alterations and expression of relevant genes in triple-negative breast cancer. Genes Chromosomes Cancer (2008) 1.26
Mucinous carcinoma of the breast is genomically distinct from invasive ductal carcinomas of no special type. J Pathol (2010) 1.25
A high-resolution integrated analysis of genetic and expression profiles of breast cancer cell lines. Breast Cancer Res Treat (2009) 1.23
Distribution and significance of caveolin 2 expression in normal breast and invasive breast cancer: an immunofluorescence and immunohistochemical analysis. Breast Cancer Res Treat (2007) 1.06
CD44 is overexpressed in basal-like breast cancers but is not a driver of 11p13 amplification. Breast Cancer Res Treat (2009) 1.05
Breast cancer epigenetics: normal human mammary epithelial cells as a model system. J Mol Med (Berl) (2008) 1.03
Immunophenotypic and genomic characterization of papillary carcinomas of the breast. J Pathol (2011) 0.95
Basal and triple-negative breast cancers: impact on clinical decision-making and novel therapeutic options. Clin Breast Cancer (2008) 0.91
Genomic gain of 5p15 leads to over-expression of Misu (NSUN2) in breast cancer. Cancer Lett (2009) 0.91
Genetic discoveries propagate new epigenetic drugs. J Natl Cancer Inst (2012) 0.77
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med (2009) 24.75
International network of cancer genome projects. Nature (2010) 20.35
Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell (2010) 17.48
Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature (2009) 13.45
Triple-negative breast cancer. N Engl J Med (2010) 11.39
The landscape of cancer genes and mutational processes in breast cancer. Nature (2012) 11.24
Mutational processes molding the genomes of 21 breast cancers. Cell (2012) 11.22
The life history of 21 breast cancers. Cell (2012) 10.59
Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer (2004) 10.31
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet (2010) 8.41
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med (2012) 6.93
Breast cancer molecular profiling with single sample predictors: a retrospective analysis. Lancet Oncol (2010) 6.88
Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol (2010) 6.42
Resistance to therapy caused by intragenic deletion in BRCA2. Nature (2008) 5.85
Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res (2005) 5.70
Basal-like breast cancer: a critical review. J Clin Oncol (2008) 5.64
Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell (2009) 4.76
BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell (2010) 4.66
FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res (2010) 3.89
Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res (2009) 2.91
Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment. Breast Cancer Res Treat (2009) 2.85
Expression profiling of purified normal human luminal and myoepithelial breast cells: identification of novel prognostic markers for breast cancer. Cancer Res (2004) 2.82
Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer. Nat Med (2011) 2.77
Molecular evolution of breast cancer. J Pathol (2005) 2.69
Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer. Nature (2012) 2.66
Dissecting the heterogeneity of triple-negative breast cancer. J Clin Oncol (2012) 2.64
Comprehensive sampling of gene expression in human cell lines with massively parallel signature sequencing. Proc Natl Acad Sci U S A (2003) 2.64
Genetic interactions in cancer progression and treatment. Cell (2011) 2.54
Functional viability profiles of breast cancer. Cancer Discov (2011) 2.44
Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol (2010) 2.42
Identification of direct transcriptional targets of (V600E)BRAF/MEK signalling in melanoma. Pigment Cell Melanoma Res (2009) 2.42
Analysis of PALB2/FANCN-associated breast cancer families. Proc Natl Acad Sci U S A (2007) 2.41
A distinct spectrum of copy number aberrations in pediatric high-grade gliomas. Clin Cancer Res (2010) 2.37
Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res (2010) 2.33
The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. J Pathol (2010) 2.23
Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis. J Pathol (2009) 2.17
FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas. Clin Cancer Res (2006) 2.15
Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival. Breast Cancer Res (2007) 2.12
Sox2: a possible driver of the basal-like phenotype in sporadic breast cancer. Mod Pathol (2007) 2.09
The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat (2008) 2.06
Establishment of the epithelial-specific transcriptome of normal and malignant human breast cells based on MPSS and array expression data. Breast Cancer Res (2006) 2.03
High frequency of coexistence of columnar cell lesions, lobular neoplasia, and low grade ductal carcinoma in situ with invasive tubular carcinoma and invasive lobular carcinoma. Am J Surg Pathol (2007) 2.00
Emerging therapeutic targets in endometrial cancer. Nat Rev Clin Oncol (2011) 1.99
A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res (2010) 1.96
Histone H3.3. mutations drive pediatric glioblastoma through upregulation of MYCN. Cancer Discov (2013) 1.93
An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers. Breast Cancer Res Treat (2009) 1.93
Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Res (2013) 1.92
Histological and molecular types of breast cancer: is there a unifying taxonomy? Nat Rev Clin Oncol (2009) 1.91
Genetic heterogeneity and cancer drug resistance. Lancet Oncol (2012) 1.91
Whole genome sequencing of matched primary and metastatic acral melanomas. Genome Res (2011) 1.90
Homozygous BUB1B mutation and susceptibility to gastrointestinal neoplasia. N Engl J Med (2010) 1.90
Challenges translating breast cancer gene signatures into the clinic. Nat Rev Clin Oncol (2011) 1.86
Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat (2007) 1.84
Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol (2011) 1.83
Lobular neoplasia of the breast revisited with emphasis on the role of E-cadherin immunohistochemistry. Am J Surg Pathol (2013) 1.83
The generation and utilization of a cancer-oriented representation of the human transcriptome by using expressed sequence tags. Proc Natl Acad Sci U S A (2003) 1.79
β-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation. Mod Pathol (2010) 1.79
Identification of a disease-defining gene fusion in epithelioid hemangioendothelioma. Sci Transl Med (2011) 1.79
The biological, clinical and prognostic implications of p53 transcriptional pathways in breast cancers. J Pathol (2010) 1.79
Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas. J Pathol (2010) 1.79
FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis. Breast Cancer Res (2007) 1.78
Multiple immunofluorescence labelling of formalin-fixed paraffin-embedded (FFPE) tissue. BMC Cell Biol (2008) 1.75
Targeting the DNA repair defect of BRCA tumours. Curr Opin Pharmacol (2005) 1.75
Promyelocytic leukemia nuclear bodies associate with transcriptionally active genomic regions. J Cell Biol (2004) 1.74
Breast cancer precursors revisited: molecular features and progression pathways. Histopathology (2010) 1.72
Tumor size and survival in breast cancer--a reappraisal. Nat Rev Clin Oncol (2010) 1.70
Columnar cell lesions of the breast: the missing link in breast cancer progression? A morphological and molecular analysis. Am J Surg Pathol (2005) 1.70
Tiling path genomic profiling of grade 3 invasive ductal breast cancers. Clin Cancer Res (2009) 1.68
Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations. Cell Cycle (2011) 1.65
PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors. Sci Transl Med (2010) 1.64
Clinical and biological significance of E-cadherin protein expression in invasive lobular carcinoma of the breast. Am J Surg Pathol (2010) 1.63
Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis. Clin Cancer Res (2007) 1.61
Unlocking pathology archives for molecular genetic studies: a reliable method to generate probes for chromogenic and fluorescent in situ hybridization. Lab Invest (2006) 1.59
Histological types of breast cancer: how special are they? Mol Oncol (2010) 1.58
High-throughput RNA interference screening using pooled shRNA libraries and next generation sequencing. Genome Biol (2011) 1.53
Array CGH using whole genome amplification of fresh-frozen and formalin-fixed, paraffin-embedded tumor DNA. Genomics (2005) 1.52
Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis. Breast Cancer Res Treat (2008) 1.51
PPM1D is a potential therapeutic target in ovarian clear cell carcinomas. Clin Cancer Res (2009) 1.49
Non-existence of caveolin-1 gene mutations in human breast cancer. Breast Cancer Res Treat (2011) 1.47